Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Middle East News Digest.
Press releases published on October 25, 2025
VIBE at Global Health Exhibition 2025 Celebrates Wellness, Longevity, and the Future of Healthy Living
Powered by LiveWell from Saudi Arabia’s Ministry of Health, the new wellness program at GHE connects innovation, lifestyle, and health span RIYADH, SAUDI ARABIA, October 25, 2025 /EINPresswire.com/ -- VIBE, powered by LiveWell from the Ministry of …
Emirard Partners with SOBHA Realty to Expand Dubai Luxury Real Estate Access to Asian Investors
UAE-based Emirard, a DLD-licensed becomes the official gateway for Korean, Chinese, and Japanese investors to access premium Dubai property developments. DUBAI, DUBAI, UNITED ARAB EMIRATES, October 25, 2025 /EINPresswire.com/ -- Emirard, the UAE-based …
Quell Therapeutics to Unveil Promising Data for QEL-005, a Novel CAR-Treg Cell Therapy for Complex Autoimmune Diseases, at ACR Convergence 2025
Results from pre-clinical studies demonstrate immunomodulatory activity of QEL-005 across multiple immune cell lineages involved in complex autoimmune inflammation, including B cells, T cells and inflammatory macrophages Broad mechanism of action of QEL- …
Kyverna Therapeutics Highlights Potential of KYV-101 in Rheumatoid Arthritis with Phase 1 Data from Investigator-Initiated Trial Presented at ACR Convergence 2025
KYV-101 resulted in a profound reduction in disease-associated autoantibodies and impact on disease activity in patients with difficult-to-treat rheumatoid arthritis (RA) KYV-101 continues to demonstrate a well-tolerated profile, consistent with …
ITM Announces Analyses from Phase 3 COMPETE Data Showing Higher Objective Response Rates with n.c.a. 177Lu-edotreotide (ITM-11) vs. Everolimus Across Subgroups of Patients with GEP-NETs at NANETS 2025 Annual Symposium
Austin, Texas, October 25, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, announced analyses data from its Phase 3 COMPETE trial in patients with Grade 1 or Grade 2 somatostatin receptor (SSTR)-positive …